Global Opdivo (Nivolumab) Market 2026 strengthening immuno-oncology

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Opdivo (nivolumab) Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market for opdivo (nivolumab) has experienced significant expansion in recent years. Its value is projected to rise from $8.34 million in 2025 to $9.01 million in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. The growth observed in prior periods can be linked to the approval of pd-1 inhibitors, an escalating global cancer burden, the inherent limitations of chemotherapy, compelling clinical trial results, and the increasing adoption of immunotherapy by oncologists.

The Opdivo (nivolumab) market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $12.13 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This growth during the projected period can be ascribed to factors such as broadening into novel oncology applications, the development of combination therapy approaches, enhanced biomarker-driven patient selection, an uptick in cancer diagnoses, and increased expenditure on oncology healthcare. Key trends anticipated for the forecast timeframe encompass the expanding application of immune checkpoint inhibitors, a growing embrace of combination immunotherapy protocols, the proliferation of PD-1 based cancer therapies, wider utilization across various cancer types, and an emphasis on achieving improved long-term survival results.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp

What Drivers Are Influencing The Opdivo (nivolumab) Market?

The Opdivo (nivolumab) market is expected to expand due to the rising occurrence of non-small cell lung cancer in the future. Non-small cell lung cancer (NSCLC) represents the most common form of lung cancer, accounting for approximately 85% of all lung cancer cases. The increasing frequency of non-small cell lung cancer (NSCLC) is primarily linked to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo operates by inhibiting the PD-1 receptor on immune cells, thereby strengthening the body’s immune response to identify and combat cancer cells. For instance, in 2024, the American Cancer Society, a US-based health organization, documented 234,580 new lung cancer diagnoses in the US. Of these, 80% were non-small cell lung cancer (NSCLC), marking an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Consequently, the growing incidence of non-small cell lung cancer is fueling the growth of the Opdivo (nivolumab) market.

What Major Segment Divisions Exist Within The Opdivo (nivolumab) Market?

The opdivo (nivolumab) market covered in this report is segmented –

1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL

2) By Dosage: Injection, Solution, Other Dosages

3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

4) By End-User: Hospitals, Clinics, Other End Users

How Are Trends Shaping The Direction Of The Opdivo (nivolumab) Market?

Key companies involved in the Opdivo (nivolumab) market are prioritizing the development of sophisticated combination therapies to improve treatment effectiveness, address resistance mechanisms, and extend applications across various cancer forms. This approach involves the strategic application of Opdivo (nivolumab) alongside other therapeutic agents, such as chemotherapy, aiming to deliver a more exhaustive treatment regimen for individuals with advanced cancer. Notably, in October 2024, the Food and Drug Administration, a US-based federal agency, granted approval for Opdivo (nivolumab) when combined with platinum-doublet chemotherapy as a neoadjuvant treatment, subsequently followed by single-agent nivolumab as adjuvant therapy following surgery, specifically for adults diagnosed with resectable non-small cell lung cancer who lack known EGFR or ALK mutations. This significant approval facilitates the use of Opdivo both prior to and after surgical procedures, thereby improving therapeutic results for qualifying patients.

Which Companies Are Leading Innovation In The Opdivo (nivolumab) Market?

Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical

Read the full opdivo (nivolumab) market report here:

https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-

Which Regions Are Expected To Experience Rapid Expansion In The Opdivo (nivolumab) Market?

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Opdivo (nivolumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19914&type=smp

Browse Through More Reports Similar to the Global Opdivo (nivolumab) Market 2026, By The Business Research Company

Nivolumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795